The public offering of HANXBIO-B was oversubscribed by 3,073 times, with a 1% chance of winning one lot

HANXBIO-B (03378.HK) announced the results of its IPO, with the Hong Kong public offering receiving 3,074.09 times subscription, and a 1% chance of winning for one board lot (100 shares), with a subscription of 600,000 shares needed to secure one lot. The international offering recorded 5.78 times subscription. The final offer price is HKD 32, at the upper limit, raising a net amount of HKD 531 million. The shares are expected to be listed on Tuesday (23rd).

The biotechnology company HANXBIO plans to globally offer 18.321 million shares, with 10% allocated for public offering. The offer price ranges from HKD 28 to HKD 32. Seven cornerstone investors, including Fudex Resources Investment, Sage Partners Master Fund, Guotai Junan Securities Investment, TFI Investment Fund SPC, Main Source Capital, YStem Holding, and Chunlei Capital, subscribed a total of 2.9178 million shares, accounting for 15.93% of the total offering. The final date for the lock-up commitment is June 22, 2026